Retrospective Clinical Study on Integrated Chinese and Western Medicine in Treatment of Limited-Stage Small Cell Lung Cancer  

作　　者：QI Run-zhi HE Shu-lin LI Yue ZHAO Yu-wei GENG Liang HE Jie CHENG Meng-qi HU Jia-qi LI Cong-huang HUA Bao-jin 

机构地区：[1]Department of Oncology,Guang’anmen Hospital,China Academy of Chinese Medicine Sciences,Beijing(100053),China [2]Graduate School,Beijing University of Chinese Medicine,Beijing(100029),China [3]Department of Integrated Traditional Chinese and Western Medicine Oncology,Henan Cancer Hospital,Zhengzhou(100053),China

出　　处：《Chinese Journal of Integrative Medicine》2023年第8期675-682,共8页中国结合医学杂志（英文版）

基　　金：the Science and Technology Innovation Project of the China Academy of Chinese Medical Sciences(No.CI2021A01808);the Natural Science Foundation of Beijing(No.7212189);the Outstanding Young Scientific and Technological Talents(Innovation)Training Program of China Academy of Chinese Medical Sciences(No.ZZ15-YQ-026)。

摘　　要：Objective: To investigate the efficacy of integrated Chinese and Western medicine extending the progression-free survival(PFS) and overall survival(OS) of limited-stage small-cell lung cancer(LS-SCLC) patients after the first-line chemoradiotherapy. Methods: The data of 67 LS-SCLC patients who received combined treatment of Chinese medicine(CM) and Western medicine(WM) between January 2013 and May 2020 at the outpatient clinic of Guang’anmen Hospital were retrospectively analyzed. Thirty-six LS-SCLC patients who received only WM treatment was used as the WM control group. The medical data of the two groups were statistically analyzed. Survival analysis was performed using the product-limit method(Kaplan–Meier analysis). The median OS and PFS were calculated, and survival curves were compared by the Log rank test. The cumulative survival rates at 1, 2, and 5 years were estimated by the life table analysis. Stratified survival analysis was performed between patients with different CM administration time. Results: The median PFS in the CM and WM combination treatment group and the WM group were 19 months(95% CI: 12.36–25.64) vs. 9 months(95% CI: 5.96–12.04), respectively, HR=0.43(95% CI: 0.27–0.69, P <0.001). The median OS in the CM and WM combination group and the WM group were 34.00 months(95% CI could not be calculated) vs. 18.63 months(95% CI: 16.43–20.84), respectively, HR=0.40(95% CI: 0.24–0.66, P<0.001). Similar results were obtained in the further stratified analysis of whether the duration of CM administration exceeded 18 and 24 months(P<0.001). Conclusion: The combination treatment of CM and WM with continuing oral administration of CM treatment after the first-line chemoradiotherapy for LS-SCLC patients produced better prognosis, lower risks of progression, and longer survival than the WM treatment alone.(Registration No. Chi CTR2200056616)

关 键 词：limited-stage small cell lung cancer combination of Chinese and Western medicine overall survival progression-free survival Chinese medicine 

分 类 号：R734.2[医药卫生—肿瘤]